secwatch.observer — SEC 8-K summary
======================================

Issuer:     XWELL, Inc. (XWEL)
CIK:        0001410428
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001104659-25-035179
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XWELL reports FY 2024 revenue $33.9M (+13% YoY), net loss narrows to $16.9M
---------------------------------------------------------------------------

- Revenue $33.9M (+13% YoY); gross margin rose to 26.3% from 12.2%.
- Net loss attributable to XWELL narrowed to $16.9M from $27.7M in 2023.
- CDC extended Traveler-based Genomic Surveillance Program for 3 years; base value $53.7M, ceiling $85.7M.
- Closed $4M private placement in Jan 2025; plans to acquire medical spas in select metros in 2025.
- Cash & equivalents $4.6M, marketable securities $7.3M, no long-term debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410428/000110465925035179/0001104659-25-035179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410428/000110465925035179/tm2512312d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-035179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer